บริการทางเทคนิค
ต้องการความช่วยเหลือหรือไม่ ทีมนักวิทยาศาสตร์ที่มีประสบการณ์ของเราอยู่ที่นี่เพื่อคุณ
ให้เราช่วยเหลือbiological source
human placenta
Quality Level
grade
Molecular Biology
form
buffered aqueous solution
mol wt
~50 kDa
concentration
30,000-50,000 units/mL
shipped in
dry ice
storage temp.
−20°C
General description
Ribonuclease inhibitor works to inhibit RNase activity by forming a tight, non-covalent 1:1 complex. It is human placenta. It inhibits RNases A, B, and C. It will not inhibit RNases H, 1, T1, S1 Nuclease, SP6, T7 RNA Polymerase, T3 RNA Polymerase, AMV Reverse Transcriptase, M-MLV Reverse Transcriptase, or Taq Polymerase. The inhibitor can be removed by phenol extraction or by heating to 65°C for 10 minutes.
Application
Suitable for use in
- in vitro inhibition of ribonucleases
- cDNA synthesis
- RT-PCR
- in vitro transcription and translation
Useful for in vitro inhibition of ribonucleases, including procedures like cDNA synthesis, RT-PCR, and in vitro transcription and translation.
Biochem/physiol Actions
Inhibits RNase by forming a tight, non-covalent 1:1 complex.
Inhibits RNase by forming a tight, non-covalent 1:1 complex. Also inhibits angiogenin, a neovascularization promoter which is homologous with RNase A.
Physical form
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
Other Notes
One unit will reduce the activity of 5 ng of ribonuclease A by 50% in a cytidine 2′:3′-cyclic monophosphate system.
Ribonuclease Inhibitor is provided as a solution in 20 mM HEPES-KOH( pH 7.6), 50 mM KCl, 8 mM DTT and 50% glycerol.
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
This inhibitor of RNase activity is isolated from human placenta and supplied as a buffered aqueous glycerol solution.
คลาสการจัดเก็บ
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter
เลือกจากเวอร์ชันล่าสุด:
มีผลิตภัณฑ์นี้อยู่แล้วใช่หรือไม่?
ค้นหาเอกสารข้อมูลสำหรับผลิตภัณฑ์ที่คุณเพิ่งซื้อได้ในคลังเอกสาร
เนื้อหาที่เกี่ยวข้อง
Instructions
Mariona Estapé Senti et al.
Journal of controlled release : official journal of the Controlled Release Society, 341, 475-486 (2021-12-11)
PEGylation of lipid-based nanoparticles and other nanocarriers is widely used to increase their stability and plasma half-life. However, either pre-existing or de novo formed anti-PEG antibodies can induce hypersensitivity reactions and accelerated blood clearance through binding to the nanoparticle surfaces
Sabahattin Kaymakoglu et al.
Antimicrobial agents and chemotherapy, 49(3), 1135-1138 (2005-02-25)
The success of alpha interferon (IFN-alpha) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-alpha and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age
Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A.
P Blackburn et al.
The Journal of biological chemistry, 254(24), 12488-12493 (1979-12-25)